Injex Pharma Inc (fka )

[blackleguan]

INJEX Pharma AG signs exclusive Distribution Agreement for USA / Minimum Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty Kits in the first year

INJEX Pharma AG / Key word(s): Contract

04.09.2012 / 15:37


INJEX Pharma AG signs exclusive Distribution Agreement for USA / Minimum Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty Kits in the first year

INJEX Pharma AG ISIN: DE000A0STYL7

Berlin, 04 September 2012

Berlin - Newly founded '21 Medical Technologies LLC.,' (21 MT) located in Fort Lauderdale, Florida, will exclusively market and distribute INJEX30 Systems in the United States. INJEX30 syringes without a needle may be used in multiple medical, cosmetic and anesthetic applications and marketed via traditional pharmaceutical and emerging life science modalities. INJEX30 targeted disease states and delivery systems include diabetes, local and dental anesthetics, allergy and fertility treatments, vaccinations, erectile dysfunction and growth hormones. '21 MT' is a perfect partner in the US and it's an exciting time for INJEX Pharma AG as we continue to execute on our global mission while simultaneously introducing the SHIREEN Beauty Kit utilizing a 'Poring method' in the United States.' Andy Rösch, CEO INJEX Pharma AG.

The signed distributor agreement includes a minimum volume of 70,000 INJEX30 Systems, 25,000 SHIREEN Beauty Kits and 300,000 SHIREEN Fluid Units. The First shipment will commence during the month of September.

'Product launches in the United States must be carefully orchestrated across many modalities including direct to the consumer. The United States' healthcare industry appears to be in early stages of its transformation which presents an opportune time to align our innovative technology with a 'High profile personality.' '21 MT' has the ability to raise immediate awareness for both INJEX30 Systems and SHIREEN Beauty Kits through its media reach and seasoned team of professionals. We look forward to working closely with '21 MT' as they prepare to deploy significant resources across modalities. This multi-faceted approach will be necessary to build brand awareness with an emphasis on 'service excellence.' This agreement is a 'Home run' for the end users who will benefit from a syringe delivery system without a needle.' Sylwin Grinman, Director International Sales and Marketing at INJEX Pharma AG.

'We are excited to begin marketing our innovative 'Poring method' with SHIREEN Beauty Kits in the world's biggest beauty market. '21 MT' was founded with an appreciation for challenges when dealing with big markets and we are comfortable '21 MT' will exceed distribution expectations and establish new benchmarks for 'service excellence' in this industry. We will be increasing our production capacities in the short-term and developing necessary logistical contingencies to meet future demand. '21 MT' will consummate this agreement in the days ahead, with payments on the way, triggering exclusivity, as terms for initial shipments are met. Shortly thereafter, we expect to conduct a press conference with 21 Medical Technologies LLC, elaborating on our vision, steps for executing in the US and defining details related to this agreement.' Andy Rösch, CEO INJEX Pharma AG.



Contact:

Andy Rösch
CEO
INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Tel.: [phone]
[e-mail]
www.injex.com

Sylwin Grinman
Managing Director
INJEX Pharma USA
1922 NE 119 RD
North Miami Beach - FL - 33181
USA
Tel.: [phone]
[e-mail]


End of Corporate News

source:
http://www.dgap.de/news/corporate/injex-pharma-signs-exclusive-distribution-agreement-for-usa-minimum-purchase-injex-systems-and-shireen-beauty-kits-the-first-year_42269_731650.htm